Last reviewed · How we verify
Oral contraceptive
At a glance
| Generic name | Oral contraceptive |
|---|---|
| Also known as | Drospirenone and Ethinylestradiol Tablets, Yousi Yue, ethinyl estradiol [EE] and norgestimate [NGM]), Ethinyl Estradiol and Levonorgestrel, ethinylestradiol + levonorgestrel |
| Sponsor | Peking Union Medical College Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Estrogen, Diet, Genetics and Endometrial Cancer
- Anxiety and Depression in Adolescent PCOS (NA)
- Polycystic Ovary Syndrome in Type 1 Diabetes
- A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) (PHASE2)
- Efficacy of Low-dose Percutaneous Electrical Stimulation in Patients With Erectile Dysfunction. (NA)
- A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants (PHASE1)
- A Research Study Looking Into the Effect of NNC0519-0130 on Blood Levels of a Birth Control Pill and Emptying of the Stomach in Women After Menopause (PHASE1)
- The Influence of Combined Oral Contraception on the DEvelopment and progRession of Chronic venoUs diSeases (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral contraceptive CI brief — competitive landscape report
- Oral contraceptive updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI